Ignite Creation Date:
2024-05-05 @ 11:55 AM
Last Modification Date:
2024-10-26 @ 9:16 AM
Study NCT ID:
NCT00179608
Status:
COMPLETED
Last Update Posted:
2019-11-08
First Post:
2005-09-13
Brief Title:
Study of the Combination of Lenalidomide and DTIC Dacarbazine in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
Sponsor:
Celgene
Organization:
Celgene
Study Overview
Official Title:
Phase I Safety Study of the Combination of Lenalidomide and DTIC Dacarbazine in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy
Status:
COMPLETED
Status Verified Date:
2019-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will determine the MDT of intravenous DTIC when administered in combination with a fixed dose of oral lenalidomide in subjects with metastatic malignant melanoma previously untreated with systemic chemotherapy This study will evaluate the safety and preliminary efficacy of the combination of lenalidomide and DTIC Subjects will be receive lenalidomide for 14 consecutive days and DTIC on day one of each 21 day cycle
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None